Could a simple supplement protect HIV-Exposed babies from infections?
NCT ID NCT05282485
First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This study tests whether a synbiotic supplement (a mix of a prebiotic called 2'-FL HMO and a probiotic called B. infantis) can reduce infections and improve growth in infants who were exposed to HIV but are not infected themselves. About 140 infants will receive either the supplement or a placebo from 4 to 24 weeks of age. Researchers will track infections, growth, and development up to 72 weeks old.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Synbiotic (2'-FL human milk oligosaccharide + Bifidobacterium infantis probiotic)
What this could lead to
If it works, this could offer a simple dietary supplement to help HIV-exposed infants fight infections and grow better, reducing health gaps compared to unexposed babies.
What could go wrong
This is a small, early-stage trial with 140 infants, so results may not apply broadly. The supplement may cause digestive discomfort or show no benefit over placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Worcester Campus of Stellenbosch University (SU)
Stellenbosch, Western Cape, 7599, South Africa